Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ra-223 in PSMA PET Selected Prostate Cancer
NCT05924672Phase 2Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by University of California, San Francisco. Started Aug 2024; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05924672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924672.